CD19/CD22 CAR-T cell therapies are commonly used to treat B-ALL and large B cell lymphoma (LBCL), resulting in high remission rates and preventing antigen-negative relapse [57–59]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.